

The following table summarizes the disaggregation of revenue by product and region:

Dollars in Millions	Year Ended December 31,		
	2020	2019	2018
Prioritized Brands			
<i>Revlimid</i>	\$ 12,106	\$ 1,299	\$ —
<i>Eliquis</i>	9,168	7,929	6,438
<i>Opdivo</i>	6,992	7,204	6,735
<i>Orencia</i>	3,157	2,977	2,710
<i>Pomalyst/Imnovid</i>	3,070	322	—
<i>Sprycel</i>	2,140	2,110	2,000
<i>Yervoy</i>	1,682	1,489	1,330
<i>Abraxane</i>	1,247	166	—
<i>Empliciti</i>	381	357	247
<i>Reblozyl</i>	274	—	—
<i>Inrebic</i>	55	5	—
<i>Onureg</i>	17	—	—
<i>Zeposia</i>	12	—	—
Established Brands			
<i>Vidaza</i>	455	58	—
<i>Baraclude</i>	447	555	744
Other Brands ^(a)	1,315	1,674	2,357
Total Revenues	\$ 42,518	\$ 26,145	\$ 22,561
United States	\$ 26,577	\$ 15,342	\$ 12,586
Europe	9,853	6,266	5,658
Rest of World	5,457	4,013	3,733
Other ^(b)	631	524	584
Total Revenues	\$ 42,518	\$ 26,145	\$ 22,561

(a) Includes BMS and Celgene products in 2020 and 2019.

(b) Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.

Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized upon the adoption of ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affecting contract assets or contract liabilities were not material during the year ended December 31, 2020 and 2019. Revenue recognized from performance obligations satisfied in prior periods was \$338 million in 2020 and \$411 million in 2019, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales. Contract assets were not material at December 31, 2020 and 2019.

Sales commissions and other incremental costs of obtaining customer contracts are expensed as incurred as the amortization periods would be less than one year.

Note 3. ALLIANCES

BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. BMS refer to these collaborations as alliances and its partners as alliance partners.